Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533167 | 0.85 | PIK3CD (0.34) | PIK3CDHSD11B1ALDH1A1KMT2AKDM4E | |
| SCHEMBL27648357 | 0.83 | HSD11B1 (0.33) | PIK3CDHSD11B1ALDH1A1KMT2AKDM4E | |
| SCHEMBL9917292 | 0.83 | PIK3CD (0.53) | PIK3CDALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL21551654 | 0.82 | HSD11B1 (0.33) | PIK3CDHSD11B1ALDH1A1KMT2AKDM4E | |
| SCHEMBL23594266 | 0.81 | KMT2A (0.41) | PIK3CDHSD11B1ALDH1A1TACR1KMT2A | |
| SCHEMBL4312389 | 0.79 | SIGMAR1 (0.39) | HSD11B1ALDH1A1KMT2AMEN1SIGMAR1 | |
| SCHEMBL22007125 | 0.79 | FASN (0.41) | PIK3CDHSD11B1ALDH1A1TACR1KMT2A | |
| SCHEMBL17943670 | 0.79 | ALDH1A1 (0.39) | HSD11B1ALDH1A1TACR1KMT2AKDM4E | |
| SCHEMBL10254140 | 0.79 | BLM (0.43) | HSD11B1ALDH1A1TACR1KMT2AMEN1 | |
| SCHEMBL13338120 | 0.79 | GAA (0.55) | ALDH1A1TACR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | claimed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | claimed |
| EP-1781661-A2 | VASOPRESSIN V1A ANTAGONISTS | Ferring B.V. (NL) | 2007-05-09 | — | — | EP | claimed |
| EP-1632494-A1 | Vasopressin v1a antagonists | FERRING B.V. (NL) | 2006-03-08 | — | — | EP | claimed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | PIK3CD 2747/4885HSD11B1 888/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.